The QualityStocks Daily Wednesday, April 7th, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(BNSO) $9.8900 +44.26%

Tip.us(DVLP) $0.0063 +40.00%

MarketBeat(OUST) $9.8700 +25.73%

The QualityStocks Daily Stock List

OZOP Energy Solutions Inc. (OTC: OZSC)

MarketClub Analysis, MarketBeat, StockMarketWatch, Schaeffer's, QualityStocks, InvestorPlace, Trading Concepts, TopPennyStockMovers, StreetInsider, Small Cap Firm, Jason Bond, INO Market Report and BUYINS.NET reported earlier on OZOP Energy Solutions Inc. (OZSC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OZOP Energy Solutions Inc. (OTC: OZSC) is focused on the design, manufacture and distribution of power electronics and endoscopic instruments.

The firm invents and develops power supplies, converters, inverters and ultra-high power chargers for various applications in the maritime, aircraft ground support, heavy industrial and defense sectors. OZOP Energy Solutions Inc. serves consumers across the globe.

The firm, which was known as OZOP Surgical Corp before changing its name, has its headquarters in Warwick, New York. OZOP Energy Solutions Inc. was established on July 17, 2015 and operates through the Hong Kong and United States geographical segments.

OZOP Energy Solutions also provides surgical devices, instrumentation and implants, which focus on neurological, spine and pain management specialties and procedures. The firm’s AC (alternating current) and DC (direct current) power supplies, which are available in ratings from 5KW (kilowatt) to 20 MW (megawatt), are utilized in multi-pulse silicon control rectifier, insulated gated bipolar transistor design. They provide low output noise, precise regulation, low ripple and also help achieve efficiency. The firm also offers a frequency converter for any military, industrial or commercial application with power ranges from 4KVA to 500 KVA (kilovolt-ampere). This is in addition to providing 400 hertz aircraft ground support equipment and manufacturing all types of power inverters, including electrostatic precipitators, power transmissions, solar cell power stations, AC/AC inverters, DC/AC inverters and DC/DC inverters.

OZOP Energy Solutions Inc. recently announced that they’d be developing the first contract energy systems for non-grid solutions. This move aligns with the firm’s expansion plan and with energy use in the U.S. set to increase significantly, the energy production industry is bound to need help in meeting the population’s needs, which is where the firm is set to gain hefty returns for its shareholders.

OZOP Energy Solutions Inc. (OZSC), closed Wednesday’s trading session at $0.09015, off by 7.0619%, on 53,886,751 volume. The average volume for the last 3 months is 242,649,767 and the stock's 52-week low/high is $0.004499999/$0.50.

CASI Pharmaceuticals Inc. (NASDAQ: CASI)

MarketClub Analysis, MarketBeat, StockMarketWatch, TraderPower, Wall Street Mover, TopPennyStockMovers, Promotion Stock Secrets, InvestorPlace, The Online Investor, StreetInsider, QualityStocks, PoliticsAndMyPortfolio and BUYINS.NET reported earlier on CASI Pharmaceuticals Inc. (CASI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CASI Pharmaceuticals Inc. (NASDAQ: CASI) (FRA: ENMN) is a biopharmaceutical firm that is engaged in the acquisition, development and commercialization of pharmaceutical products and innovative therapeutics that address various unmet medical needs.

The firm primarily operates in China, Canada and the United States as well as internationally, and serves patients across the globe. CASI Pharmaceuticals has its headquarters in Rockville, Maryland and was established in 1991. The firm was known as EntreMed Inc. before changing its name in 2014 to CASI Pharmaceuticals Inc.

CASI Pharmaceuticals is engaged in building a pipeline through various business development transactions that are mutually beneficial and develops as well as commercializes its drug candidates in Macau, Hong Kong, Taiwan and China. The firm is party to distribution agreements with Riemser Pharma GmbH, Pharmathen Global BV and China Resources Guokang Pharmaceuticals Co. Ltd as well as licensing agreements with Cleave Therapeutics Inc., Black Belt Therapeutics Ltd, BioInvent International AB and Juventas Cell Therapy Ltd.

CASI Pharmaceuticals Inc.’s product pipeline includes an IV formulation which is administered to multiple myeloma patients before stem cell transplantation as a conditioning treatment, known as EVOMELA. The majority of the firm’s revenue is generated from the product sales of this particular candidate, which recently concluded phase 1 clinical studies in China. The company’s other products include an investigative product indicated for the treatment of B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia called CNCT19; a treatment indicated for myelodysplastic syndrome, acute myeloid leukemia, lymphomas and solid tumors, dubbed CB-5339; a treatment for multiple myeloma christened CID-103; a treatment for Philadelphia chromosome-negative ALL in adult patients called MARQIBO; a treatment for non-Hodgkin’s lymphoma patients dubbed ZEVALIN and BI-1206, which is undergoing a phase 1/2 trial in combination with Keytruda, an anti-PD1 therapy, for the treatment of solid tumors.

As of December 2020, CASI Pharmaceuticals’ partner, Juventas Cell Therapy Ltd. had been granted Breakthrough Designation for its CNCT19 candidate, developed for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Considering CASI has co-commercial rights to the candidate and is also a Juventas shareholder, this is good news not only for B-ALL patients but also for the firm whose reach continues to grow in Greater China.

CASI Pharmaceuticals Inc. (CASI), closed Wednesday’s trading session at $2.05, off by 4.6512%, on 1,751,673 volume. The average volume for the last 3 months is 1,228,438 and the stock's 52-week low/high is $1.46000003/$3.90000009.

CTI BioPharma Corp. (NASDAQ: CTIC)

Greenbackers, Willy Wizard, Momentum Traders, The Street, Hit and Run Candle Sticks, The Momentum Traders Network, MarketBeat, MicrocapVoice, DrStockPick, CRWEFinance, PennyOmega, Daily Markets, InvestorPlace, StockHotTips, PennyToBuck, StreetInsider, CRWEWallStreet, Marketbeat.com, BestOtc, Wall Street Resources, CRWEPicks, BUYINS.NET, TradersPro, Penny Invest, OTCtipReporter, Kiplinger Today, StockEgg, MarketClub Analysis, Willy's First Alert Stocks, OTC Picks, HotOTC, PennyStocks24, PickPennyStocks, Penny Stock Rumble, CoolPennyStocks, OTCReporter, OTCPicks, PennyTrader Publisher, StockMarketWatch, Real Pennies, SmarTrend Newsletters, Penny Stock Explosion, TraderPower, MonsterStocksPicks, The Sandman, Street Insider, Daily Trade Alert, PennyTrader, HyperGrowthStock, Research Driven Alerts, WealthMakers, Canadian Microcap Report, Stock Traders Chat, Jason Bond, Profit Confidential, QualityStocks and Research Driven Investor reported earlier on CTI BioPharma Corp. (CTIC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CTI BioPharma Corp. (NASDAQ: CTIC) (FRA: CEPS) is a biopharmaceutical firm that is engaged in acquiring, developing and commercializing targeted therapies for blood related cancers as well as breast, neck, brain and ovarian cancers in the United States.

CTI BioPharma Corp. has its headquarters in Seattle, Washington and was founded in September 1991 by Louis A. Bianco, Jack W. Singer and James A. Bianco. The firm serves consumers in the state of Washington and changed its name in May 2014 from Cell Therapeutics Inc. to CTI BioPharma Corp.

CTI BioPharma Corp. is party to a collaboration and license agreement with Vernalis Ltd, S*BIO Pte Ltd and Teva Pharmaceutical Industries Ltd. The firm, whose other subsidiaries include CTI Life Sciences and Aequus Biopharma, is developing a possible sarcoma treatment dubbed brostallicin through its Systems Medicine subsidiary.

CTI BioPharma Corp. develops treatments that are less toxic and more effective against different forms of cancer. Its candidates include pacritinib, which has been developed for the treatment of myelofibrosis in adult patients. The drug is currently undergoing phase 3 clinical trials for myelofibrosis. Other candidates include pixuvri, which is indicated for the treatment of non-Hodgkin’s lymphoma as well as other tumorous cancers. This drug has conditional approved in Europe. The firm also evaluates opaxio, which is indicated for the treatment of solid tumors.

CTI BioPharma Corp. announced recently that it had concluded a rolling NDA submission to the U.S. FDA, which sought the approval for its pacritinib candidate as a myelofibrosis treatment. The firm’s candidate could address various unmet medical needs of myelofibrosis patients who suffer from serious thrombocytopenia. The drug is set to launch before the end of 2021, assuming a successful priority NDA review. This move will not only be good for the company’s growth but also for the patients who’ll be assisted by this drug.

CTI BioPharma Corp. (CTIC), closed Wednesday’s trading session at $2.56, off by 2.2901%, on 1874928 volume. The average volume for the last 3 months is 910,211 and the stock's 52-week low/high is $0.860000014/$4.13000011.

Net Savings Link Inc. (OTC: NSAV)

Investor Development Group, QualityStocks, Real Pennies, TheMicrocapNews, Stockgoodies, SmallCapVoice and PennyTrader Publisher reported previously on Net Savings Link Inc. (NSAV), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Net Savings Link Inc. (OTC: NSAV) is an integrated technology firm that offers turnkey technological solutions to the legal medical marijuana and hemp industries as well as other areas of the medical industry.

The firm provides its services in the United States and has its headquarters in Cresco, Pennsylvania. Net Savings Link Inc. was established on February 21, 2007.

Net Savings Link Inc. operates through the Global Distribution Corporation, which is a subsidiary it owns. Through it, the firm markets and distributes natural remedies, wellness and supplement products. The firm also offers health and wellness products, including probiotics, mineral and vitamin supplements as well as other nutraceuticals health supplements, under its Nutra Horizon brand name.

Net Savings Link Inc. is also focused on providing various services which include e-commerce and software solutions. Additionally, it provides information technology, patents and trademarks, advisory services and financial services, among others. Net Savings Link Inc. also provides hemp based beer under the brand names Angry Tiger Beer and Tiger Hemp Beer.

Net Savings Link Inc. recently announced that it had acquired a major 25% stake in SBCDF Investment Inc., which is scheduled to launch its STUX product soon. The token; SBC Token Unix X, will be marketed through all major social channels like Medium, Twitter, Telegram, Discord and Reddit. Given that SBC is a force to reckon with not only on Wall Street but also across the globe, NSAV is in for an exciting and fruitful era, which will help the company grow and avail various benefits to its shareholders.

Net Savings Link Inc. (NSAV), closed Wednesday’s trading session at $0.02166, up 7.7612%, on 25,930,979 volume. The average volume for the last 3 months is 159,411,222 and the stock's 52-week low/high is $0.000000999/$0.069700002.

DarkPulse Inc. (OTC: DPLS)

We reported beforehand on DarkPulse Inc. (DPLS), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

DarkPulse Inc. (OTC: DPLS) is a technology-security firm which is engaged in the designing, development, marketing and distribution of a suite of engineering, installation and security management solutions to governments and industries. The firm serves consumers in Canada and is based in New York, the United States. DarkPulse Inc. was incorporated in 1989 by Dennis M. O’Leary. Before changing its name, the firm was known as Klever Marketing Inc.

DarkPulse Inc.’s objective is to deliver monitoring and security systems with applications in mine safety, the oil and gas industry, pipelines and border security. The firm provides a pair of security platforms; Ultra-high sensitivity sensors and Fiber-based monitoring systems. The former involves analytical technologies and equipment that is used to detect trace amounts of illicit drugs, chemical warfare agents and explosives while the latter is made up of software and hardware combinations that detect changes in the structural integrity of infrastructure.

DarkPulse Inc. also provides the DARKPULSE system which has the ability to determine temperature, strain, pressure, pipe-wall thickness, corrosion and wall deformation using sensor data gathered in real time. In addition to this, the firm is in the process of developing advertising terminals that can be attached to shopping cart handlebars. The terminals will offer advertisers an opportunity to influence potential consumers at the point of purchase.

DarkPulse Inc. recently appointed a new Chief Operating Officer, who brings to the table more than 3 decades of experience in security and safety, project management and business development, both in the private and public sector. With the firm moving into sales, manufacturing and distribution from research and development, having an experienced executive to help achieve both long and short term operational goals will help improve efficiency as well as lay a better foundation for the firm’s overall growth.

DarkPulse Inc. (DPLS), closed Wednesday’s trading session at $0.0159, off by 4.7904%, on 58,099,573 volume. The average volume for the last 3 months is 203,700,387 and the stock's 52-week low/high is $0.000009999/$0.050999999.

Starco Brands, Inc. (STCB)

We reported earlier on Starco Brands, Inc. (STCB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Starco Brands, Inc. is a consumer packaged goods (CPG) company. It focuses on unique and behavior changing products. The Company develops products across a variety of categories. These include Household Cleaning, Personal Care, OTC (Over-the-Counter), Food, Beverage & Spirits, and DIY (Do-It-Yourself) Hardware. The Company formerly went by the name Insynergy Products, Inc. It changed its name to Starco Brands, Inc. in September of 2017. Starco Brands is based in Santa Monica, California and lists on the OTC Markets’ OTCQB.

Starco Brands’ core competency is inventing technologies, marketing, building trends, pushing awareness, and penetrating media, social and otherwise. In addition, the Company’s core competency is executing leading-edge pull-through strategies with its billion dollar global partners.

Starco Brands has its Breathe® product. Breathe is the first aerosol cleaning line with 100 percent of ingredients meeting the Environmental Protection Agency's (EPAs) Safer Choice criteria. Instead of LPG (Liquified Petroleum Gas), Breathe is powered by air. Included in the Breathe aerosol line is a patent-pending hand sanitizer spray that covers large areas of skin quickly and minimizes human-to-human contact.

The Breathe line includes furniture polish, multi-purpose cleaner, a stainless steel polish, as well as a bathroom cleaner. The Breathe fragrance free hand sanitizer is child resistant with a twist-locking spray tip. It can be used in a wide array of settings. These include households, hospitals, healthcare facilities, airports, transportation terminals, hotels, and other institutions.

Starco Brands previously announced that its Breathe® product line of spray hand sanitizers and household cleaners are now available to purchase online from Amazon and Walmart. The Breathe® line was approved for sale by Amazon after undergoing a 60 day approval process to provide safe and best in class products amid heightened levels of scrutiny. Furthermore, the Breathe Hand Sanitizing Spray and Breathe Household Cleaning line have both earned the Good Housekeeping Seal.

Starco Brands, Inc. (STCB), closed Wednesday’s trading session at $0.65, up 96.3153%, on 10,126 volume. The average volume for the last 3 months is 2,613 and the stock's 52-week low/high is $0.305000007/$3.00.

EGF Theramed Health Corp. (EVAHF)

Epic Stock Picks, Wolf of Penny Stocks, QualityStocks, Make Penny Stocks Great Again, OTCtipReporter, Penny Pick Finders, PennyStockScholar, Profitable Trader Authority, StockOnion, PennyStockProphet, HotOTC, Buzz Stocks, Damn Good Penny Picks, Penny Stock 101, StockHideout, PennyStockLocks, BeatPennyStocks, Penny Picks, StockRockandRoll, Fierce Analyst, Broad Street, Insider Financial, Leading Penny Stocks, PennyPickGains, Pennystockmania, Small Cap Firm, StockWireNews, Wealth Insider Alert and Penny Stock Titans reported  previously on EGF Theramed Health Corp. (EVAHF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

EGF Theramed Health Corp. is a technology company headquartered in Vancouver, British Columbia. It is focused in the healthcare and life sciences sector to develop a personalized healthcare system. EGF Theramed Health has now been concentrating on using CBD (cannabidiol) derived from hemp as a core component. The Company formerly went by the name Theramed Health Corporation. It changed its name to EGF Theramed Health Corp. in October of 2019. EGF Theramed Health lists on the OTC Markets Group’s OTCQB.

The Company, via its subsidiaries, has assets and technologies involved in extracting and purifying CBD extracts, creating formulations through its key scientists, and with its medical device technology monitoring capabilities. EGF Theramed Health provides automated online services for solving common health problems. The Company’s objective is to be the first to offer a total quality assured integrated "Natural Products Health Monitoring System" to improve one’s health conditions. Its online system is targeted primarily at "practicing patients" interested in normalizing blood pressure, blood glucose, and body weight. EGF Theramed Health’s device enables physiologically interactive health applications (apps) useful in testing, tracking, and treating common health conditions.

In essence, the Company’s vision is to help improve health through personalized medical care (including Natural Products usage monitoring and its effects on the cardiovascular system), molecular biology, nutraceutical solutions, and genetics. EGF Theramed Health continues to develop products, technologies, and diagnostic tools centered on hemp-derived cannabidiol. It has also began its due diligence and research procedures in search of new investment opportunities in the psilocybin sector to diversify and strengthen its existing asset base. The Company has also started to research psilocybin and psychedelics extraction and processing for its Las Vegas extraction lab.

EGF Theramed Health has closed on the joint venture (JV) transaction with Pharmadelic Labs Corp., previously announced on May 4, 2020. With the announced JV and Share Purchase Agreement with Pharmadelic Labs and its shareholders, EGF Theramed Health acquired a 30 percent equity interest in Pharmadelic Labs. Pharmadelic Labs is a private Nevada corporation. It has research facilities in the Provinces of British Columbia and Alberta. With this Agreement, the parties will collaborate at EGF Theramed Health's lab facilities in Nevada for the further development and commercial exploitation of certain of Pharmadelic Lab's intellectual property (IP) focused on creating biosynthesis pathways for psilocybin.

EGF Theramed Health previously announced that its JV partner, Pharmadelic Labs, secured additional lab facility space in order to expand its research and development (R&D) of proprietary processes to help create pharmaceutical grade psilocybin-derived ingredients in a synthetic lab environment. Pharmadelic Labs has a leased space at a lab facility in Burnaby, British Columbia.

EGF Theramed Health also announced that Global Green Parrot Laboratories, Inc. (GGP) entered into a Memorandum of Understanding (MOU) with Greenfield Global Projects, Inc. Greenfield is a private company with extensive cannabis related projects in Jamaica and corporate offices in Vancouver. Green Parrot Labs Corp., a JV partner in which EGF Theramed Health holds a 40 percent equity interest, holds a 70 percent equity interest in GGP.

EGF Theramed Health Corp. (EVAHF), closed Wednesday’s trading session at $0.111, up 23.608%, on 65,010 volume. The average volume for the last 3 months is 73,546 and the stock's 52-week low/high is $0.043999999/$1.45000004.

Guyana Goldstrike, Inc. (GYNAF)

QualityStocks and The Cervelle Group reported previously on Guyana Goldstrike, Inc. (GYNAF), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Guyana Goldstrike, Inc. engages in the acquisition, exploration, and development of resource properties. The Company explores for gold deposits. It is developing the Marudi Gold Project, which has a 17-year mining license and is situated in Guyana, South America. The Company previously went by the name Swift Resources, Inc. It changed its name to Guyana Goldstrike, Inc. in March of 2017. Incorporated in 2006, Guyana Goldstrike is headquartered in Vancouver, British Columbia. It also has an office in Georgetown, Guyana. The Company lists on the OTC Markets.

Historic diamond drilling completed on the Marudi Gold Project by previous operators have delineated two zones of gold mineralization. These are Mazoa Hill and the Marudi North zones. A mineral resource estimate has been completed on the Mazoa Hill Zone. Data analyzed suggests the zone is open to mineralization in manifold directions and at depth.

Guyana Goldstrike, via its recent exploration program, has discovered a third mineralized zone, named Toucan Ridge. It is positioned roughly 1000 meters to the northeast of the Mazoa Hill Zone. In addition to the known gold zones and the new Toucan Ridge zone, Guyana Goldstrike has greater than 45 sq. kms of underexplored land. The Company’s belief is that the greater land position has first-rate upside potential for the discovery of new mineralized zones via the development of earlier and newly identified mineralized bedrock targets on the Project.

Previously, Guyana Goldstrike announced that it signed a definitive gold forward purchase agreement, dated January 24, 2020, with an arms-length investor for proceeds of up to US$9,000,000, for the Marudi Gold Project. With this Agreement, the Investor will make an initial payment of US$2,000,000 on or before April 14, 2020. Subsequently, a second payment of US$7,000,000 will be advanced within 30 days of a royalty interest in the Project in favour of the Investor having been registered. The proceeds will enable Guyana Goldstrike to finalize its purchase of the Project and further explore and develop the resource potential of the Property.

Guyana Goldstrike, Inc. (GYNAF), closed Wednesday’s trading session at $0.1261, up 32.7368%, on 13,500 volume. The average volume for the last 3 months is 4,434 and the stock's 52-week low/high is $0.072999998/$0.162496.

GGX Gold Corp. (GGXXF)

We reported previously on GGX Gold Corp. (GGXXF), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

GGX Gold Corp. is a gold exploration company listed on the OTCQB. It is rejuvenating an historic British Columbia gold camp with new discoveries. The Company previously went by the name Revolver Resources, Inc. It changed its name to GGX Gold Corp. in October 2016. GGX Gold has its corporate headquarters in Vancouver, British Columbia.

The Company’s Gold Drop project encompasses an area of greater than 5,600 hectares. The Gold Drop Project is positioned 40 km from Grand Forks, British Columbia on geologically prospective ground in the well-mineralized Greenwood Mining District. GGX Gold has discovered two new significant gold bearing vein structures - the C.O.D. and Everest veins. Also, GGX owns nine percent of a private syndicate centered on project generation within the Golden Triangle.

Drilling and trenching during the 2017 exploration season and the 2018 season have led to the discovery of significant gold bearing structures. These structures are predominant throughout the property. Gold Drop’s historical production totals 7572 tonnes at an average grade of 5.2 g/t Au and 93.4 g/t Ag. The 7572 tonnes was mined from three main veins - Amandy, North Star and Gold Drop.

Recently, GGX Gold summarized highlights of the 2018 exploration season on the Gold Drop Property in Southern British Columbia. The program concentrated on the C.O.D vein in the Gold Drop Southwest Zone. During the drilling program GGX also conducted mechanical trenching on manifold targets.

The Company completed 71 diamond drill holes on the C.O.D vein. High-grade intersections include 107.5 g/t gold and 880 g/t silver over 6.90 meters core length and 129 g/t gold and 1,154 g/t silver over 7.28 meter core length. GGX extended the C.O.D vein 160 m to the southwest via drilling.

The Company completed 19 diamond drill holes on the Everest vein. In addition, it discovered the southern extension of the Gold Drop vein via mechanical trenching. It also completed 30 m of trenching on the Silent Friend Vein. GGX completed a thorough trenching program in the C.O.D North area of the property.

GGX Gold previously announced it requested tellurium re-analysis of select drill core samples from the Fall 2018 diamond drill program at the Gold Drop Property in southern British Columbia. The Fall 2018 drill program was conducted at the C.O.D. Vein in the Gold Drop Southwest Zone. Numerous drill core samples from drill holes COD18-67 and COD18-70 surpassed the upper 500 grams per tonne (g/t) analytical limit for tellurium. The samples returned high grade values for gold and silver. These samples will be re-analyzed to ascertain tellurium grades.

GGX Gold Corp. (GGXXF), closed Wednesday’s trading session at $0.1388, up 30.0843%, on 60,000 volume. The average volume for the last 3 months is 7,942 and the stock's 52-week low/high is $0.052799999/$0.223299995.

Navient Corporation (NASDAQ: NAVI)

StreetInsider, MarketClub Analysis, MarketBeat, The Online Investor, Kiplinger Today, InvestorPlace, Daily Trade Alert, Zacks, Trades Of The Day, TradersPro, Schaeffer's, Marketbeat.com, Penny Sleuth, SureMoney, Trading Concepts, Whiskey & Gunpowder, The Street, Wealth Insider Alert, MarketWatch, Investopedia, StreetAuthority Daily, Barchart, Insider Wealth Alert, Darwin Investing Network, Investors Daily Edge, iStockAnalyst, CRWEWallStreet, Cabot Wealth, Money Morning, Penny Invest, ResearchOTC, Stansberry Research, StockEgg, Street Insider, Super Stock Picker, The Growth Stock Wire, The Stock Dork, TopStockAnalysts, TrendAdvisor, Wall Street Greek and SmallCapInvestor.com reported previously on Navient Corporation (NAVI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Navient Corporation (NASDAQ: NAVI) traded at a new 52-week high today of $14.59. So far today approximately 321,000 shares have been exchanged, as compared to an average 30-day volume of 2.4 million shares.

In the past 52 weeks, shares of Navient Corporation have traded between a low of $6.14 and a high of $14.59 and is now at $14.59, which is 137% above that low price.

Navient Corporation (NASDAQ:NAVI) is currently priced 1.3% above its average consensus analyst price target of $14.40.

Navient Corp is a financial services company that provides education loan management and business processing services to education, healthcare, and government clients at the federal, state, and local levels. The company operates in Delaware, western New York, northern Pennsylvania, Indiana, Tennessee, Texas, and Virginia, among other locations. The company has three primary reportable business segments: Federal Education Loans, Consumer Lending and Business Processing. The company's fourth and other segment relates to financial results of the company's holding company, including activities related to repurchases of debt, corporate liquidity portfolio, and unallocated overhead and regulatory-related costs.

Navient Corporation (NAVI), closed Wednesday’s trading session at $14.51, up 1.115%, on 1,154,121 volume. The average volume for the last 3 months is 2,225,800 and the stock's 52-week low/high is $6.14499998/$14.6000003.

iStar Inc. (STAR)

MarketBeat, The Online Investor, MarketClub Analysis, Trades Of The Day, internet, Daily Trade Alert, Zacks, Trading Concepts, The Street, StreetInsider, StockMarketWatch, SiliconValley, InvestorPlace and GorillaTrades reported previously on iStar Inc. (STAR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Shares of iStar Inc. (NYSE: STAR) traded at a new 52-week high today of $18.55. Approximately 136,000 shares have changed hands today, as compared to an average 30-day volume of 622,000 shares.

iStar Inc finances, invests in, and develops real estate and real estate-related projects. The company operates through four segments. The real estate finance segment comprises a portfolio of senior and subordinated loans secured by commercial real estate assets. The net lease segment is engaged in lease transactions across office, industrial, retail, hotel, entertainment, and other property types, primarily to corporate tenants. The operating properties segment owns, operates, and revitalises office, retail, and hotel properties. The land and development segment is engaged in land sales, as well as design, entitlement, and development of residential communities. The company's primary source of revenue is net lease income.

Based on a current price of $18.51, iStar Inc. is currently 1.6% above its average consensus analyst price target of $18.22.

In the past 52 weeks, shares of iStar Inc. have traded between a low of $7.13 and a high of $18.55 and is now at $18.51, which is 160% above that low price.

iStar Inc. (STAR), closed Wednesday’s trading session at $18.50, up 0.162426%, on 434,952 volume. The average volume for the last 3 months is 562,570 and the stock's 52-week low/high is $7.30000019/$18.5499992.

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC)

Greenbackers, The Street, MarketClub Analysis, Streetwise Reports, StreetInsider, TraderPower, MarketBeat, BUYINS.NET, StockEgg, Promotion Stock Secrets, OTC Picks, PennyStocks24, Marketbeat.com, HotOTC, CRWEWallStreet, QualityStocks, CoolPennyStocks, MicrocapVoice, Profit Confidential, StockMarketWatch, Street Insider, The Online Investor, The Bull Report, MegaPennyStocks, StockRich, PennyTrader Publisher, The Momentum Traders Network, MadPennyStocks, Penny Invest, PennyStockVille, PennyInvest, Wall Street Resources, BullRally, Stock Traders Chat, Energy and Capital, TopPennyStockMovers, SmarTrend Newsletters, ChartPoppers, Stockpalooza, InvestorsUnderground, The Penny Play, FNNO Newsletters, Wealth Daily, Investment Contrarians, NYC Marketing Inc, Stock Rich, Penny Detectives, Penny Stock Finder, PennyOmega, WealthMakers, Stock Source, Schaeffer's, SmallCapVoice, Stealth Stocks, Stock Beast, Stock Market Watch and Momentum Traders reported beforehand on Cyclacel Pharmaceuticals Inc. (CYCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cyclacel (NASDAQ: CYCC), a biopharmaceutical company developing innovative medicines based on cancer cell biology, has closed an underwritten public offering of 2,078,214 shares of its common stock, including 271,071 additional shares per the full exercise of the over-allotment option granted to the underwriters.

 

Cyclacel secured approximately $14.5 million in gross proceeds, with each of the shares sold at the public offering price of $7.00. The company intends to use the proceeds from the offering to support its growth strategy, as well as for working capital and general corporate purposes, including research and development expenses and capital expenditures. Roth Capital Partners acted as co-manager for the offering.

To view the full press release, visit https://ibn.fm/8l41b

Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For more information about the company, visit www.Cyclacel.com.

Cyclacel Pharmaceuticals Inc. (CYCC), closed Wednesday’s trading session at $7.15, off by 0.417827%, on 105,022 volume. The average volume for the last 3 months is 733,505 and the stock's 52-week low/high is $3.11999988/$19.25.

The QualityStocks Company Corner

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE) was featured today in a publication from Green Car Stocks, examining how if you have been following the news lately, you may have noticed that the share prices of electric vehicle (“EV”) companies have taken a hit. However, this doesn’t mean that you should engage your parachute and bail out, as this price correction doesn’t necessarily mean the bull run of these stocks is over. Here are key reasons why the outlook is still bullish for EV stocks, according to a leading global wealth management firm.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Wednesday’s trading session at $11.85, up 1.5424%, on 134,510 volume. The average volume for the last 3 months is 701,155 and the stock's 52-week low/high is $1.64999997/$20.0783996.

Recent News

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D metal printing industry, has been selected by Ermaksan Innovative Technologies to provide its in-process quality assurance (IPQA(R)) technology, PrintRite3D(R), as a factory option on its ENAVISION 3D metal additive machines and will be integrated with the Materialise Control Platform ("MCP"). The collaboration commences with an initial contract for a single system from Ermaksan to install PrintRite3D at a new customer site in Turkey. Initially, Sigma Labs will install the PrintRite3D system at the Bursa, Turkey-based Ermaksan facility and expects to be in the position to certify the Ermaksan ENAVISION system as PrintRite3D-ready before ultimately moving the system to the end user's facility. To view the full press release, visit https://ibn.fm/sFw5c

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Wednesday’s trading session at $3.94, up 0.254453%, on 617,073 volume. The average volume for the last 3 months is 5,601,528 and the stock's 52-week low/high is $1.95000004/$9.75.

Recent News

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF)

The QualityStocks Daily Newsletter would like to spotlight HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF).

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has received conditional approval to offer its proprietary CBD products on Tmall, the world’s largest cross-border online marketplace. This news follows the company’s recent announcement that its Probulin Probiotics would also be available on Alibaba Group Holding’s Tmall Global (“Tmall”). The third most-visited website in the world, Tmall represents more than 750 million potential new consumers living across mainland China, Hong Kong, Macau and Taiwan. To view the full press release, visit http://ibn.fm/fdlMY

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF) is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

  • Natural Health Retailers
  • eCommerce
  • Big Box / Food and Drug Mass
  • Doctor Practitioner
  • Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

  • Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
  • OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
  • Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:
    • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
    • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
    • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
    • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.

HempFusion Wellness Inc. (CBDHF), closed Wednesday’s trading session at $1.8785, up 4.9441%, on 88,209 volume. The average volume for the last 3 months is 102,147 and the stock's 52-week low/high is $1.61000001/$3.69000005.

Recent News

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (OTC: KAVL), a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets, has scheduled an investor call for Wednesday, April 14. Hosted by Kaival Brands CEO Niraj Patel, the call will kick off at 5 p.m. ET and will include a discussion of the company’s recent developments as well as a Q&A session. Interested parties are invited to submit pertinent questions by April 8 at investors@kaivablbrands.com. Interested individuals are also invited to participate on the call by dialing toll free 800-346-7359 in the United States and Canada, using the passcode 132056. To view the full press release, visit https://ibn.fm/3ctOT

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Wednesday’s trading session at $1.64, up 9.3333%, on 115,282 volume. The average volume for the last 3 months is 453,478 and the stock's 52-week low/high is $0.045000001/$3.65000009.

Recent News

ISW Holdings Inc. (OTC: ISWH)

The QualityStocks Daily Newsletter would like to spotlight ISW Holdings Inc. (OTC: ISWH).

ISW Holdings (OTC: ISWH), a global brand management holdings company with commercial operations in telehealth and cryptocurrency mining, has signed an agreement with GPL Ventures (“GPL”) to eliminate more than $2.4 million in convertible promissory notes. According to the announcement, the agreement will cover all convertible debt held by GPL, which represents more than 92% of ISWH’s outstanding convertible debt. To view the full press release, visit https://ccw.fm/X15yC

ISW Holdings Inc. (OTC: ISWH), through its in-house initiatives and strategic partnerships, has invested in growing operations targeting the telehealth and cryptocurrency mining industries.

The company specializes in strategic brand development and early growth facilitation. Management maneuvers its proprietary companies through critical stages of market development, including conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

Mission

The company’s core mission is to enhance these sectors by implementing innovative services and products that are ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources and innovative software to establish market-leading companies and partnerships, thereby ensuring success in their chosen industries.

Cryptocurrency Mining

The start of 2021 saw a massive resurgence in interest surrounding bitcoin and cryptocurrency mining. In mid-February, bitcoin prices hit an all-time high of greater than $57,000, and heightened demand for cryptocurrency mining power has played a key role in exacerbating a global shortage of semiconductors and computer components.

With a foothold in the cryptocurrency mining space, ISW Holdings has placed significant focus on expanding its position and capitalizing on this momentum. Recent highlights include:

  • February 9, 2021: The company announced that its revolutionary Pod5 Cryptocurrency Mining Pod will be powered up into full operational launch at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania on February 12, 2021.
  • February 11, 2021: The company announced that it is in negotiations to purchase a large number of miners (between 300 and 900) in preparation for its coming Phase 3 expansion in mining volume.
  • February 23, 2021: The company announced its entry into a comprehensive Hosting and Maintenance Agreement prior to going online with its new ASIC s17 miners.
  • March 2, 2021: The company announced that it has successfully tripled its active cryptocurrency mining fleet with the addition of two new POD5IVE datacenters.

“As we continue to bring our miners online, we want our shareholders to be able to track the expansion and profitability of the company’s mining activity given the sharp rising trend in bitcoin prices,” Alonzo Pierce, President and Chairman of ISW Holdings, stated in a news release. “It currently costs about $11K in computing power to mine a single bitcoin. Bitcoin is pricing at over five times that level, making this is an exceptional ROI opportunity, and our responsibility to our shareholders is clear: continue to invest, expand and execute.”

Business Innovations

ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. Some of the company’s current holdings and partnerships include:

  • Bit5ive LLC: ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.
  • Proceso LLC: ISW Holdings has partnered with Proceso LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining.
  • PHH Health: The company’s home health division answers the growing need for home care services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care.
  • Volum: The company’s logistics and supply chain management division is designed with the core goal of increasing supply chain efficiency, which is recognized as one of the key aspects of successfully growing any business.

Market Opportunity

ISW Holdings’ recent activity in the cryptocurrency mining sector has positioned it to capitalize on the forecast expansion of the cryptocurrency market in the coming years. According to data from MarketsandMarkets, the cryptocurrency space was valued at $1.03 billion in 2019 and is projected to reach $1.40 billion in 2024, achieving a CAGR of 6.18% during the forecast period.

The report suggests that major drivers for this growth will be the transparency of the underlying blockchain technology, the high volume of remittances in developing countries, the high cost of international remittance, expected fluctuations in monetary regulations and sustained investment in the cryptocurrency space by venture capital firms.

Management Team

Terry Williams is the Chief Executive Officer and Director of ISW Holdings. Mr. Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, he amassed considerable corporate experience at UPS (NYSE: UPS), where he took several logistical roles, managing more than 2,000 employees and a budget of more than $10 billion. Mr. Williams also serves as president of Airware Transportation and Logistics and Chief Financial Officer of AVI Insurance Caribbean. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce is the company’s President and Chairman. He brings a wealth of business development and wealth management experience to the ISW team, having spent the past 20 years building recognizable brands in multiple industry sectors. Mr. Pierce has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown is Secretary, Treasurer and Director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Ms. Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

ISW Holdings Inc. (ISWH), closed Wednesday’s trading session at $0.667, up 3.4109%, on 432,134 volume. The average volume for the last 3 months is 1,551,125 and the stock's 52-week low/high is $0.0152/$1.47000002.

Recent News

Hero Technologies Inc. (OTC: HENC)

The QualityStocks Daily Newsletter would like to spotlight Hero Technologies Inc. (OTC: HENC) .

Hero Technologies (OTC: HENC), a cannabis company focused on a vertically integrated strategy, today announced that its management and insiders continue to hold HENC common shares and have not sold any shares in the open market, protect equity for legacy shareholders, and communicate company developments transparently. Hero Technologies’ management and insiders are not currently selling the shares they hold, do not plan to sell any shares in the near future, do not expect to issue any more shares to insiders, and do not anticipate any reverse splits of the company's stock. Should the aforementioned change, the company will issue an update in a press release or in any lawful manner. To view the full press release, visit: https://cnw.fm/9JmM1

Hero Technologies Inc. (OTC: HENC) is a cannabis company with a vertically integrated business model and plan that includes cannabis genetic engineering, farmland for medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, retail operations and dispensaries that make the organization a multi-state operator (MSO).

The company was founded in 2004 and is headquartered in Dover, Delaware.

Portfolio

The company holds the majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation firm focused on providing optimal conditions to enhance photosynthesis and cultivation. Hero Technologies is planning expansion in cultivation and dispensary operations in Colorado through wholly owned subsidiary Mile High Green LLC, while expansion in Massachusetts is planned through another wholly owned subsidiary, MassCannabis LLC.

Hero Technologies also owns and operates HighlyRelaxing.com under Highly Relaxing LLC and recently acquired the assets of V Brokers LLC, now operating as Veteran Hemp Co. at VeteranHempCo.com.

BlackBox Systems and Technologies LLC

BlackBox Systems and Technologies LLC markets a proprietary cannabis aeroponic cultivation system designed for the large-scale production of top-shelf cannabis products. BlackBox offers the optimal conditions to enhance photosynthesis and promote the cultivation of large flowering plants. The system’s dry room, process room and secure storage were designed for precise control through each phase of the cannabis lifecycle. Weekly harvests are achieved using 13 separate BlackBox systems in independent modules.

The system provides a series of key benefits, including:

  • High-pressure nutrient delivery, with no nutrient or PH deficiencies
  • Sterile, 100% nutrient solution
  • Drain to Waste (no reuse of wastewater)
  • Low water usage (1 gallon per plant per day)
  • Constant PH and EC in reservoirs
  • Modular design (1 to 100 pods in any configuration)
  • Innovative proprietary engineering
  • Minimal cleanup
  • Media-less growing, suspended in the air, with no media waste
  • No pesticides

Highly Relaxing LLC

Highly Relaxing LLC is an emerging Henderson, Nevada-based operation dedicated to providing customers with honestly labeled, high-quality hemp-derived CBD products. Its current offerings include a topical CBD cream that provides localized relief from potential discomfort.

Veteran Hemp Co.

Veteran Hemp Co.’s mission is to provide a quality, consistent and delicious product for Americans looking to enjoy the hemp smoking experience. Its product is brought in by only the finest farming operations delivering the best genetics. Veteran Hemp Co. has its own custom harvest plans, drying facilities and all of the logistics that fall between. Veteran Hemp Co. prides itself on being a veteran-approved company.

Market Outlook

The global legal cannabis market is anticipated to reach $84 billion by 2028, expanding at a CAGR of 14.3% from 2021 to 2028. The driving factor for this forecast expansion is the increasingly widespread legalization of cannabis for medical and recreational use. Recreational use accounted for 60.3% of industry revenue in 2020.

North America provided the largest revenue share in the cannabis market, accounting for 91.1% of the global market in 2020. Due to the early legalization of medical and recreational cannabis in the region, the customer pool has increased exponentially (https://nnw.fm/snpHh).

The global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a CAGR of 21.2% and reach $13.4 billion by 2028. North America is considered the most progressive region for cannabis and its derived products, with the highest number of CBD companies being based on the continent. The B2B (business to business) segment dominates the CBD industry, accounting for the largest revenue share at 59.6% in 2020 (https://nnw.fm/cGxXQ).

With its vertically integrated business model and development into a multi-state operator across multiple sectors of the cannabis industry, Hero Technologies is uniquely positioned to capitalize on the fast-growing market and the growing number of opportunities emerging as a result of legalization and increased popularity among consumers.

Management Team

Gina Serkasevich, CPA, CMA, is the Chief Executive Officer, Treasurer and Secretary of the Hero Technologies. She previously worked for Holloman Corporation as its Director of Finance beginning in June 2012 and was appointed Chief Financial Officer of Holloman Energy Corporation in August 2014. She has more than 30 years of domestic and international corporate accounting and finance experience. She served as U.S. Controller for EFLO Energy Inc., a company focused on the acquisition, exploration and development of oil and gas assets in North America. Prior to 2012, Ms. Serkasevich worked in the oil and gas tanker transportation industry as a Regional Financial Manager for AET Inc. Limited (2011-2012), as a Financial Consultant for OSG Ship Management Inc. (2009-2011) and as a Financial Controller/CFO for Stena Bulk LLC (1998-2008). During her 11-year tenure at Stena Bulk LLC, she established the financial, accounting and reporting requirements for its new joint ventures and tanker pools with Sonanagol USA and held the Company Secretary position on both of those companies’ boards of directors.

Dan McCarthy is the company’s Corporate Development Manager. He has spent more than 12 years in the institutional investment community, holding various investment banking and private equity executive roles. Thus far, he has been a part of over $1 billion in transactional value ranging from debt and equity to acquisitions and diversities throughout his career. Mr. McCarthy’s most recent role was Managing Director at Petro Capital, a Dallas-based private equity and investment bank. He began his career working for a private international consulting firm based in Washington, D.C., helping corporations and funds expand into non-G7 countries utilizing World Bank financing. He is also a graduate of the University of Kansas School of Business and completed the Mergers and Acquisitions program at the New York Institute of Finance.

James Rowland is Hero Technologies’ Marketing Advisor and an expert in marketing and e-commerce. He has held many high-level marketing and business-related roles. He is the Founder and current CEO of PerfectCheckout.com and the current Business Development Specialist at Fulfillment.com. Mr. Rowland has held multiple high-level positions throughout his career, which have provided him with the experience needed to bring success-backed marketing leadership skills to his current role with the company.

Hero Technologies Inc. (HENC), closed Wednesday’s trading session at $0.14, up 14.7541%, on 1,357,563 volume. The average volume for the last 3 months is 1,174,706 and the stock's 52-week low/high is $0.020999999/$0.317400008.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable (OTC: FDBL), a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications, has announced March numbers for its proprietary Fan Pass platform. Artist sign-ups for the platform continue to climb, seeing “spectacular” growth in March, reported the company, with 575 new artists joining the Fan Pass community, an 81% increase over the 317 artists that joined in February. Other performance metrics grew as well, with a 100% increase in live events and performances in addition to increased monthly platform impressions, fan/user sessions and social media followers, likes and reach. To view the full press release, visit http://ibn.fm/1WcZk

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Wednesday’s trading session at $0.021, up 5.00%, on 4,842,053 volume. The average volume for the last 3 months is 6,177,934 and the stock's 52-week low/high is $0.007799999/$0.174999997.

Recent News

Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF)

The QualityStocks Daily Newsletter would like to spotlight Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF).

Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF), a proven, consumer-driven cannabis company in both the medicinal and recreational marijuana market segments, is planning to make an official corporate name change (https://cnw.fm/I4VDo). The company announced that it will be changing its name to Chalice Brands Ltd. at its annual and special meeting (“AGM”), which is slated for May 10, 2021.

Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) is a premier consumer-driven cannabis company powered by the Chalice retail and consumer brands. GLH takes a diversified approach to growth through innovation, strategic partnerships and retail expansion, as well as a brand portfolio focusing on health and wellness. The company features best in class retail cannabis experiences backed by cultivation, processing and developing wholesale distribution. With over 160 employees, GLH is one of the largest cannabis operators in Oregon. The company holds licensing in Oregon, as well as partnerships for manufacturing and distribution in California. Its current product portfolio includes recognizable brands such as Chalice(TM), Elysium Fields(TM), GOLDEN(TM), Jackpot(TM) and RXO(TM).

Brands

Golden Leaf Holdings offers an innovative product line that addresses current market needs and looks forward to meet emerging trends. The company’s goal is to offer something for everyone through the wholesale and retail marketplaces. Its current product offerings include:

Chalice(TM)

The Chalice Farms(TM) brand is focused on how cannabis enhances lives and ignites purpose. By offering the highest quality of cannabis in an array of flower, extracts, oils, edibles and full-body care products, the brand provides full efficacy in both the retail and wholesale markets. The Chalice Farms team has over 100 years of combined cannabis experience and continues to be an industry leader for both medical and recreational cannabis use – providing state-of-the-art farming practices, excellent retail and complete product innovation.

Elysium Fields(TM)

Elysium Fields(TM) is a “soil-to-oil” craft cannabis brand intended for cannabis connoisseurs who want the highest quality THC and boldest terpene flavors. Made from small-batch live resin, Elysium Fields creates an experience described as a remarkable entourage effect. The C-Cell cartridge has a 30% strain specific HTE with a 70% high THC distillate. The resin is created from a sustainable, organic garden flower that is flash-frozen upon harvest to preserve the terpenes for a heavenly experience.

RXO(TM)

RXO(TM) features Chalice Farms’ purest and most versatile Rick Simpson Oil products. RXO was developed by the Steele brothers in collaboration with medical professionals and is a potent, strain-specific Ethanol Hash Oil (EHO) purified through a proprietary process. Through this process, various consumption methods can be accommodated, including edible, topical, sublingual and smoking (shatter and vape).

GOLDEN(TM)

GOLDEN(TM) offers a wide variety of craft cannabis products for a diverse population of cannabis users. Sourced from the finest raw materials from local growers, GOLDEN products are high-quality and innovative. Premium cannabis distillate vaporizer cartridges and fruit chew edibles made from organic ingredients are made using the most flavorful terpenes for enhanced health, wellness and enjoyment. Products are distributed online and through Chalice Farms or other dispensary partners.

Jackpot(TM)

Jackpot(TM) products offer a powerful combination of flavor and potency. With 70% THC content in each cartridge, Jackpot adds full-spectrum cannabinoids and flavorful infused terpenes in short-run limited strains for on-the-go fun seekers. The quality hardware of the cartridges makes them easily recyclable and guarantees to produce a large volume draw each time.

Cannabis Market Outlook

In 2020, the legal cannabis market was valued at approximately $23 billion, and it is expected to top $73.6 billion in revenue by 2027, growing at a CAGR of 18.1% during the forecast period (https://ibn.fm/LdkhG). One of the biggest factors driving the cannabis market’s growth is legalization around the world.

As cannabis sales generally increased during the pandemic, Golden Leaf Holdings achieved record financials for Q3 2020, reporting quarterly revenue of $6.2 million, a year-over-year increase of 42%. For the first time in its history, the company also reported positive cash flow in excess of $417,000 (https://ibn.fm/LY1b2).

Golden Leaf Holdings is uniquely positioned to capitalize on the growth of both the medicinal and recreational marijuana market segments through a rich product offering that successfully addresses current consumer needs.

Management Team

Jeff Yapp is the CEO and President of Golden Leaf Holdings Ltd. He has created a culture at GLH that operates under his mantra of ‘Crawl, Walk, Run’. He is an accomplished entrepreneur and corporate executive who has built a successful career through his ability to recognize opportunity, even when it isn’t obvious. Mr. Yapp has an extensive background in retail, marketing and entertainment. In the past, he has been committed to bringing innovation to Fortune 25 companies such as Microsoft, Kraft Foods, PepsiCo and more. As a strategic partner for Microsoft, he is an integral driver of growth for online and retail operations. He graduated with honors from the University of Michigan, majoring in Business Administration. He also graduated with honors from JL Kellogg School of Management at Northwestern University.

John Varghese is the Executive Chair of Golden Leaf Holdings and is responsible for all capital markets initiatives at GLH. His background is in mergers and acquisitions, investing, operations and capital markets, with professional experience that ranges from private equity, venture capital and investment banking to senior management positions and director roles in both private and public companies. He has served on over 20 boards, acting as the chairman of six of them.

Andrew Marchington is the company’s CFO. His public accounting career experience includes time with start-up, high-growth and enterprise-level organizations, including five years of prior cannabis industry experience. He has a rich understanding of the priorities and best practices within accounting, finance and management. Mr. Marchington’s past experience includes time with companies like Deloitte, Moss Adams, Cambia Health Solutions and C21 Investments.

John Ford, Golden Leaf Holdings’ Chief Revenue Officer and VP of Retail, is a seasoned and dynamic retail leader with extensive experience in the retail industry who has led the launch of major retail brands such as Apple and Microsoft in China and Australia. His goal is to help retailers transition their businesses to modern experiential locations where customers can engage with products and brands in new ways. At Apple, Mr. Ford was the only field expat sent to launch Apple Retail in China. He set several records for Apple while in China, not just in sales but also in inventory management and employee turnover. Mr. Ford left Apple to lead Microsoft’s international retail expansion, where he also managed its e-commerce presence.

Golden Leaf Holdings Ltd. (GLDFF), closed Wednesday’s trading session at $0.0494, up 2.9167%, on 839,986 volume. The average volume for the last 3 months is 3,507,398 and the stock's 52-week low/high is $0.009499999/$0.088100001.

Recent News

Knightscope, Inc.

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc..

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”), has announced deployment of its K5 patrol solution to a new client. The update reads, “Together with Transcend Security Solutions — one of Arizona’s largest, premier contract security providers — Knightscope brings its K5 Autonomous Security Robot to Phoenix where it will be added to the security program of the very first shopping mall in the city — Park Central Mall. To view the full update, visit https://ibn.fm/Mu8pL

Knightscope, Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities and are on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including ten Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire.

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
  • Operating for more than one million hours in the field and securing contracts across five time zones;
  • Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
  • Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With more than 10,000 investors and over $40 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to $50 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine (http://nnw.fm/l9GLX) until July 20, 2020. Concurrent with this live offering and contingent upon various factors, including raising a sufficient amount of funds and meeting applicable listing standards, the company intends to begin preparation of an S-1 format Form 1-A and Nasdaq Capital Market application in anticipation of a possible public listing of the stock at the conclusion of the Regulation A+ offering.

Company Mission — The Greater Good

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings — and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has four patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.


Recent News

chart

AmpliTech Group Inc. (NASDAQ: AMPG)

The QualityStocks Daily Newsletter would like to spotlight AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW).

AmpliTech Group (NASDAQ: AMPG, AMPGW), the provider of industry-leading SATCOM Low Noise Amplifier Solutions for the past 18 years, designs and develops top-quality microwave amplifiers using its experience, technical expertise, and superior design knowledge. AmpliTech announced that the company has received orders worth $500,000 from a major Fortune 100 defense contractor and a major satellite and cable TV broadcaster.

AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW) designs, develops and manufactures custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:

Amplifiers

Passive Components

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

  • Timely technical assistance
  • Little or no learning curve
  • Less long-term costs associated with full-time employees with benefits and salaries
  • Availability when necessary
  • Customer support with schedules, project management and on the job training
  • Access to technology
  • Partnering for manufacturing and/or complete turn-key product solution
  • Personal guidance from concept to development
  • Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 (https://nnw.fm/zqMEk). Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation (https://nnw.fm/rVzxX). The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

  • High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
  • 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
  • IoT (Internet of Things)
  • Cloud Farms, Big Data and MEC architecture
  • Quantum Supercomputers/Quantum Research
  • Deep Space Astronomy
  • Autonomous Self-Driving Vehicles
  • Telemedicine, AR/VR (Augmented and Virtual Reality)
  • Drones, UAVs (Unmanned Aerial Vehicles)
  • Cyber-security
  • Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (CPA) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

M. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

AmpliTech Group Inc. (AMPG), closed Wednesday’s trading session at $9.54, off by 6.9268%, on 775,819 volume. The average volume for the last 3 months is 664,483 and the stock's 52-week low/high is $0.540000021/$19.7999992.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

A new study recently completed by the Washington University School of Medicine in St. Louis has found that glioblastoma (“GBM”) brain cancer patients receiving the current chemotherapy standard of care had longer survivability rates if they switched from receiving treatments in the evening to receiving the treatments in the morning — encouraging news for patients with the incurable illness, as well as for neuro-oncology researchers attempting to develop improved treatments, including biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday’s trading session at $2.36, off by 2.4793%, on 135,078 volume. The average volume for the last 3 months is 1,704,666 and the stock's 52-week low/high is $1.59000003/$5.61999988.

Recent News

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

The QualityStocks Daily Newsletter would like to spotlight XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTCQB: XPHYF) was featured today in the 420 with CNW by CannabisNewsWire. Last week, the New York City police department (“NYPD”) sent out an internal memo clarifying a number of issues after Gov. Andrew Cuomo signed a bill legalizing adult-use marijuana. Among other things, the memo indicated that individuals who are at least 21 years old will no longer be liable for an arrest once they smoke marijuana in any place where people are allowed to smoke tobacco. Those places include sidewalks as well as other public spaces.

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

  • Commercialization of infectious disease diagnostics
  • Clinical validation of transdermal and sublingual drug formulations
  • Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

  • Rotigotine transdermal patch for Parkinson’s disease
  • CBD oral/sublingual strip for treatment resistant epilepsy
  • THC oral/sublingual strip for anorexia/nausea
  • CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

  • An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
  • An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

XPhyto Therapeutics Corp. (OTCQB: XPHYF), closed Wednesday’s trading session at $2.13, off by 1.1601%, on 49,266 volume. The average volume for the last 3 months is 85,134 and the stock's 52-week low/high is $1.3125/$3.0999999.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Monday's trading